Riskpilot← Back to searchSign inGet full accessRedacta Science AB
ABActiveOrg 5568041932Persögatan 10Research and experimental development on natural sciences and engineering · NACE 7210Est. 20100 employees
Revenue 2025
—
EBITDA margin
—
-74% vs 2024
Equity ratio
-78.2%
Financial strength
Net profit 2025
SEK -5K
+96% vs 2024
| Revenue | — | — |
| EBITDA | SEK -5K | -74% |
| Net profit | SEK -5K | +96% |
| Total assets | SEK 1K | -67% |
| Equity | SEK -1K | -125% |
| Employees | 0 | — |
Legal name
Redacta Science AB
Org number
5568041932
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8 april 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Föremålet för bolagets verksamhet är att direkt eller indirekt via hel- eller delägda företag bedriva forskning och utveckling inom medicinsk diagnostik liksom att bedriva marknadsföring och försäljning av produkter och tjänster inom samma område samt därmed förenlig verksamhet.
Address
Persögatan 10
Email
sofia.hiortafornas@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — |
| Staff expenses | — | −0 | −0 | −0 | −0 |
| EBITDA | −11 | −2 | −2 | −3 | −5 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −11 | −2 | −2 | −3 | −5 |
| Net financials | 695 | −1 855 | −461 | −135 | 0 |
| Profit before tax | 683 | −1 857 | −463 | −138 | −5 |
| Tax | −0 | — | — | — | — |
| Net profit | 683 | −1 857 | −463 | −138 | −5 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 457 | 605 | 142 | 4 | 1 |
| Equity | 2 347 | 490 | 27 | 4 | −1 |
| Long-term debt | 98 | 115 | 115 | 0 | — |
| Short-term debt | 12 | 0 | — | — | 2 |
| Total debt | 110 | 115 | 115 | — | 2 |
EBITDA margin
-508500.0%
This company
15.8%
Market median
-3218454% vs market
20212025
Equity ratio
-78.2%
This company
38.2%
Market median
-305% vs market
20212025
Return on equity
-499900.0%
This company
18.4%
Market median
-2716948% vs market
20212025
Net profit margin
-499900.0%
This company
8.1%
Market median
-6171705% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
2.28×
This company
0.62×
Market median
-268% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SM Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
KM | Audit | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2021 | |
| Former (1) | ||
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Redacta Science AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Krister Mattias Eriksson | Audit | 0 companies |
| Sofia Margareta Hiort af Ornäs | Chief Executive Officer | 0 companies |
| Anders Mathias Karlsson | Board of Directors | 0 companies |
| Hanna Margareta Neidenmark | Deputy Board Member | 0 companies |